Atorvastatin does not affect ischaemia-induced phosphatidylserine exposition in humans in-vivo

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 3, 2012, Pages 285-291

  Wouters, Constantijn W ^a   Meijer, Patrick ^a   Janssen, Carola I F ^a   Frederix, Geert W J ^a   Oyen, Wim J ^a   Boerman, Otto C ^a   Smits, Paul ^a   Rongen, Gerard A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Annexin A5 scintigraphy; Atorvastatin; Ischaemia reperfusion injury; Pharmacologic preconditioning; Phosphatidylserines

Indexed keywords

ATORVASTATIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PLACEBO; TECHNETIUM 99M;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TARGETING; FOREARM; FOREARM ISCHEMIA; HUMAN; HYPOTHESIS; IN VIVO STUDY; ISOTOPE LABELING; LIMB ISCHEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SCINTILLATION CAMERA;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; FOREARM; HEPTANOIC ACIDS; HUMANS; ISCHEMIA; ISCHEMIC PRECONDITIONING; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PYRROLES; REPERFUSION INJURY; YOUNG ADULT;

EID: 84859030783     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.10983     Document Type: Article

References (50)

1. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med, 1998; 129: 681-689.
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [see comments] [published erratum appears in Diabetes Care 1997 Jun; 20(6): 1048]. Diabetes Care, 1997; 20: 614-620.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996; 335: 1001-1009.
4. Saeki T, Sakuma N, Hayakawa K, Itou K, Wakami K, Tamai N, Kimura G: Low incidence of cardiac events in statin-administered patients in CAG study. J Atheroscler Thromb, 2009; 16: 172-178.
5. Osman L, Amrani M, Isley C, Yacoub MH, Smolenski RT: Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells. Nucleosides Nucleotides Nucleic Acids, 2006; 25: 1125-1128.
6. Ledoux S, Laouari D, Essig M, Runembert I, Trugnan G, Michel JB, Friedlander G: Lovastatin enhances ecto-5'- nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. Circ Res, 2002; 90: 420-427.
7. Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S, Hori M, Kitakaze M: Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation, 2004; 110: 2143-2149.
8. Urbich C, Dernbach E, Zeiher AM, Dimmeler S: Double-edged role of statins in angiogenesis signaling. Circ Res, 2002; 90: 737-744.
9. Kolyada AY, Fedtsov A, Madias NE: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension, 2001; 38: 1024-1029.
10. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998; 101: 2711-2719.
11. Bolli R: Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol, 2001; 33: 1897-1918.
12. Sack MN, Yellon DM: Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol, 2003; 41: 1404-1407.
13. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol, 2003; 41: 508-515.
14. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002; 105: 868-873.
15. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol, 2002; 13: 2288-2298.
16. Jones SP, Gibson MF, Rimmer DM, III Gibson TM, Sharp BR, Lefer DJ: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol, 2002; 40: 1172-1178.
17. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMGCoA reductase inhibitor on experimental renal ischemiareperfusion injury. Am J Nephrol, 2003; 23: 13-17.
18. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001; 285: 1711-1718.
19. De Denus S, Spinler SA: Early statin therapy for acute coronary syndromes. Ann Pharmacother, 2002; 36: 1749-1758.
20. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome. J Atheroscler Thromb, 2011; 18: 42-48.
21. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di SG: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007; 49: 1272-1278.
22. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol, 2009; 54: 558-565.
23. Thimister PW, Hofstra L, Liem IH, Boersma HH, Kemerink G, Reutelingsperger CP, Heidendal GA: In vivo detection of cell death in the area at risk in acute myocardial infarction. J Nucl Med, 2003; 44: 391-396.
24. Narula J, Strauss HW: Invited commentary: P.S.* I love you: implications of phosphatidyl serine (PS) reversal in acute ischemic syndromes. J Nucl Med, 2003; 44: 397-399.
25. Teoh NC, Ito Y, Field J, Bethea NW, Amr D, McCuskey MK, McCuskey RS, Farrell GC, Allison AC: Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology, 2007; 133: 632-646.
26. Wever KE, Wagener FADTG, Frielink C, Boerman OC, Scheffer GJ, Allison A, Masereeuw R, Rongen GA: Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic Tissue. PLoS ONE, 2011; 6: e24276. doi:10.1371/journal. pone.0024276.
27. Hale SL, Allison AC, Kloner AR: Diannexin reduces noreflow after reperfusion in rabbits with large ischemic myocardial risk zones. Cardiovasc Ther, 2011; 29: e42-52. doi: 10.1111/j.1755-5922.2010.
28. Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P: Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation, 2005; 111: 173-178.
29. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA: Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol, 2006; 48: 700-707.
30. Riksen NP, Oyen WJ, Ramakers BP, van den Broek PH, Engbersen R, Boerman OC, Smits P, Rongen GA: Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther, 2005; 78: 52-59.
31. Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman OC, Scheffer GJ, Smits P, Rongen GA: Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol, 2009; 29: 963-968.
32. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di SG: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 2004; 110: 674-678.
33. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y: Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol, 2006; 290: H1960-H1968.
34. Birnbaum Y, Lin Y, Ye Y, Merla R, Perez-Polo JR, Uretsky BF: Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther, 2008; 13: 72-79.
35. Naoumova RP, Dunn S, Rallidis L, bu-Muhana O, Neuwirth C, Rendell NB, Taylor GW, Thompson GR: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res, 1997; 38: 1496-1500.
36. Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK: Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol, 2009; 103: 437-441.
37. Schreiber-Deturmeny E, Bruguerolle B: Simultaneous high-performance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma. J Chromatogr B Biomed Appl, 1996; 677: 305-312.
38. Chyrchel M, Rakowski T, Rzeszutko L, Legutko J, Dziewierz A, Dubiel JS, Dudek D: Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol, 2006; 64: 1357-1362.
39. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med, 2007; 357: 1121-1135.
40. Javadov S, Karmazyn M: Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem, 2007; 20: 1-22.
41. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med, 1995; 182: 1545-1556.
42. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol, 1992; 148: 2207-2216.
43. Shen XD, Ke B, Zhai Y, Tsuchihashi SI, Gao F, Duarte S, Coito A, Busuttil RW, Allison AC, Kupiec-Weglinski JW: Diannexin, a novel annexin v homodimer, protects rat liver transplants against cold ischemia-reperfusion injury. Am J Transplant, 2007; 7: 2463-2471.
44. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ: Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther, 2009; 122: 30-43.
45. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ, Uretsky BF, Birnbaum Y: The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol, 2007; 293: H1918-H1928.
46. Osman L, Amrani M, Ilsley C, Yacoub MH, Smolenski RT: Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells. Mol Cell Biochem, 2008; 308: 209-217.
47. Meijer P, Wouters CW, van den Broek PH, de RM, Scheffer GJ, Smits P, Rongen GA: Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia. Hypertension, 2010; 56: 722-727.
48. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol, 2003; 92: 152-160.
49. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI: Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis, 2010; 211: 9-14.
50. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A: Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J, 2007; 71: 1348-1353.